Alpine Global Management LLC Has $1.76 Million Stock Holdings in Liquidia Co. (NASDAQ:LQDA)

Alpine Global Management LLC boosted its stake in Liquidia Co. (NASDAQ:LQDA) by 50.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,000 shares of the company’s stock after acquiring an additional 50,000 shares during the period. Alpine Global Management LLC owned 0.18% of Liquidia worth $1,764,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC boosted its position in Liquidia by 265.0% during the third quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after acquiring an additional 72,591 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Liquidia by 855.3% during the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after purchasing an additional 210,753 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Liquidia by 9.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company’s stock worth $5,040,000 after purchasing an additional 38,313 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Liquidia by 3.3% in the fourth quarter. Bank of New York Mellon Corp now owns 188,584 shares of the company’s stock valued at $2,218,000 after buying an additional 6,034 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Liquidia during the 4th quarter worth approximately $169,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Performance

Liquidia stock opened at $13.29 on Tuesday. The stock has a market cap of $1.13 billion, a PE ratio of -8.15 and a beta of 0.23. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The firm’s 50-day simple moving average is $14.59 and its 200 day simple moving average is $12.84.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, analysts predict that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the sale, the chief executive officer now owns 1,006,420 shares in the company, valued at $13,657,119.40. This represents a 1.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Michael Kaseta sold 8,283 shares of the business’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $112,400.31. Following the sale, the chief financial officer now owns 396,315 shares in the company, valued at approximately $5,377,994.55. The trade was a 2.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,678 shares of company stock valued at $416,581. Company insiders own 30.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a report on Thursday, April 10th. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $26.63.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).